文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

特异性抑制Orai1介导的钙信号可消退炎症并清除细菌:急性呼吸窘迫综合征模型研究

Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论在细菌性肺炎致急性肺损伤小鼠模型中,吸入Orai1拮抗剂ELD607可减轻中性粒细胞增多、降低细胞因子、提高生存率并减少肺部细菌,作用依赖肺泡巨噬细胞。

该临床前研究评估首创Orai1拮抗剂ELD607治疗细菌性肺炎所致ARDS。ELD607在HEK293T细胞中特异性抑制SOCE,半数抑制浓度为9 nM,在ARDS气道分泌物中稳定,并抑制ARDS患者免疫细胞的SOCE。小鼠感染铜绿假单胞菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌或多重耐药铜绿假单胞菌后经鼻给予ELD607,可显著减少中性粒细胞、改善生存、降低肺内细菌;用吸入氯膦酸盐耗竭肺泡巨噬细胞后上述效应消失。作者认为特异性抑制Orai1可能是减轻多器官炎症和治疗耐药菌的新途径。

要点

  • ELD607在HEK293T细胞中特异性抑制SOCE,半数抑制浓度为9 nM。
  • ELD607在ARDS气道分泌物中稳定,并抑制ARDS患者免疫细胞的SOCE。
  • 小鼠感染铜绿假单胞菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌或多重耐药铜绿假单胞菌后经鼻给予ELD607,显著减少中性粒细胞并改善生存。
  • ELD607显著减少肺内细菌,包括耐甲氧西林金黄色葡萄球菌。
  • 吸入氯膦酸盐耗竭肺泡巨噬细胞后,ELD607不再能消退炎症或清除细菌。

适用人群与场景

  • 临床前模型:HEK293T细胞、ARDS患者新鲜分离的免疫细胞,以及细菌性肺炎所致急性肺损伤小鼠。
  • 小鼠感染病原体包括铜绿假单胞菌、金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌或多重耐药铜绿假单胞菌。

处置流程与药物剂量

  • 小鼠经鼻给予ELD607。
  • 肺泡巨噬细胞耗竭采用吸入氯膦酸盐。

研究设计与关键结果

  • 研究类型:临床前研究,包括细胞实验与小鼠急性肺损伤模型。
  • ELD607在HEK293T细胞中特异性抑制SOCE,半数抑制浓度为9 nM。
  • ELD607在ARDS气道分泌物中稳定,并抑制ARDS患者免疫细胞的SOCE。
  • 小鼠经鼻给予ELD607后显著减少中性粒细胞并改善生存。
  • ELD607显著减少肺内细菌,包括耐甲氧西林金黄色葡萄球菌。
  • ELD607作为免疫调节剂降低细胞因子水平、减少中性粒细胞增多,并促进巨噬细胞介导的炎症消退和细菌清除。
  • 吸入氯膦酸盐耗竭肺泡巨噬细胞后,ELD607不再能消退炎症或清除细菌。
  • ARDS死亡率高达35%,目前缺乏有效治疗。

证据类型、等级与局限

  • 证据类型:临床前研究(细胞实验与小鼠模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,特异性抑制Orai1(ELD607)可能是减轻多器官炎症和治疗抗生素耐药细菌的新途径。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Acute respiratory distress syndrome (ARDS) has an unacceptably high mortality rate (35%) and is without effective therapy. Orai1 is a Ca2+ channel involved in store-operated Ca2+ entry (SOCE), a process that exquisitely regulates inflammation. Orai1 is considered a druggable target, but no Orai1-specific inhibitors exist to date. Objectives: To evaluate whether ELD607, a first-in-class Orai1 antagonist, can treat ARDS caused by bacterial pneumonia in preclinical models. Methods: ELD607 pharmacology was evaluated in HEK293T cells and freshly isolated immune cells from patients with ARDS. A murine acute lung injury model caused by bacterial pneumonia was then used: mice were infected with Pseudomonas aeruginosa, Staphylococcus aureus, methicillin-resistant S. aureus, or multidrug-resistant P. aeruginosa and then treated with ELD607 intranasally. Measurements and Main Results: ELD607 specifically inhibited SOCE in HEK293T cells with a half-maximal inhibitory concentration of 9 nM. ELD607 was stable in ARDS airway secretions and inhibited SOCE in ARDS immune cells. In vivo, inhaled ELD607 significantly reduced neutrophilia and improved survival. Surprisingly, Orai1 inhibition by ELD607 caused a significant reduction in lung bacteria, including methicillin-resistant S. aureus. ELD607 worked as an immunomodulator that reduced cytokine levels, reduced neutrophilia, and promoted macrophage-mediated resolution of inflammation and clearance of bacteria. Indeed, when alveolar macrophages were depleted with inhaled clodronate, ELD607 was no longer able to resolve inflammation or clear bacteria. Conclusions: These data indicate that specific Orai1 inhibition by ELD607 may be a novel approach to reduce multiorgan inflammation and treat antibiotic-resistant bacteria.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Ahmad S, Wrennall JA, Goriounova AS, et al. Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model. Am J Respir Crit Care Med. 2024. PMID: 37972349. doi:10.1164/rccm.202308-1393OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。